HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Xiaohu Cui Selected Research

Pneumonia (Pneumonitis)

8/2023A novel phage carrying capsule depolymerase effectively relieves pneumonia caused by multidrug-resistant Klebsiella aerogenes.
10/2022Bacteriophage Effectively Rescues Pneumonia Caused by Prevalent Multidrug-Resistant Klebsiella pneumoniae in the Early Stage.
1/2022Genetic Diversity and Pathogenic Features in Klebsiella pneumoniae Isolates from Patients with Pyogenic Liver Abscess and Pneumonia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Xiaohu Cui Research Topics

Disease

4Infections
08/2023 - 01/2022
4Non-alcoholic Fatty Liver Disease
05/2023 - 01/2023
3Pneumonia (Pneumonitis)
08/2023 - 01/2022
1Communicable Diseases (Infectious Diseases)
12/2024
1COVID-19
01/2023
1Fatty Liver
01/2023
1Inflammation (Inflammations)
01/2023
1Dysbiosis
01/2023
1Liver Abscess
01/2022

Drug/Important Bio-Agent (IBA)

3Anti-Bacterial Agents (Antibiotics)IBA
08/2023 - 01/2023
216S Ribosomal RNAIBA
12/2024 - 01/2022
2LipidsIBA
01/2023 - 01/2023
1capsular-polysaccharide galactohydrolaseIBA
08/2023
1Ethanol (Ethyl Alcohol)IBA
05/2023
13- (2- methoxyphenyl)- 5- methoxy- 1,3,4- oxadiazol- 2(3H)- oneIBA
01/2023
1Adenosine Triphosphate (ATP)IBA
01/2023
1CarbonIBA
01/2023
1DNA (Deoxyribonucleic Acid)IBA
01/2023
1Glucose (Dextrose)FDA LinkGeneric
01/2023
1Polymyxins (Polymyxin)IBA
01/2023
1Carbapenems (Carbapenem Antibiotics)IBA
01/2023
1CytokinesIBA
01/2023
1salmochelinIBA
01/2022
1Virulence Factors (Pathogenicity Factors)IBA
01/2022

Therapy/Procedure

2Phage Therapy
01/2023 - 10/2022
1Lasers (Laser)
08/2023
1Therapeutics
10/2022